Core Insights - Fangzhou Inc. received the "Excellence Award" at Gilead Sciences' 2025 Multi-Channel Conference, recognizing its achievements in AI-driven Internet healthcare solutions [1][2] - The award highlights Fangzhou's commitment to innovation and digitalization in healthcare, particularly in chronic disease management [2][4] - Fangzhou aims to deepen collaboration with Gilead to combine advanced therapies with digital health expertise for scalable care solutions [2][6] Company Overview - Fangzhou Inc. is China's leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [8] - The company specializes in tailored medical care and AI-enabled precision medicine solutions [8] Collaboration with Gilead - Fangzhou and Gilead have closely collaborated in disease prevention, treatment, and digital chronic care services, aligning their visions for improved patient outcomes [4][6] - The conference featured the launch of Gilead's initiative "Together for Health," which aims to enhance patient-centric services and strengthen digital-enabled care [5][6] Future Directions - Fangzhou plans to leverage its AI technology and full-cycle chronic disease management services while integrating Gilead's expertise in HIV, viral hepatitis, and oncology [6] - The company is exploring new "AI+ chronic care" models to advance public health [6]